Active Clinical Trials

Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy

By April 24, 2017 No Comments


Malignant Pleural Mesothelioma

Estimated Enrollment: 31

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment

Study ID Numbers: 10-134

Study First Received: December 21, 2010

Last Updated: January 4, 2017

Estimated Primary Completion Date: December 2017


Primary Outcome Measures:

To assess the 1-year progression free survival in patients|To confirm the immunogenicity of the WT-1 analog peptide vaccine|To assess the utility of using the serum marker|overall survival

Sponsors and Collaborators:

Memorial Sloan Kettering Cancer Center|United States Department of Defense

Website Link:

Leave a Reply

Call Now